TWEAK-Independent Fn14 Self-Association and NF-κB Activation Is Mediated by the C-Terminal Region of the Fn14 Cytoplasmic Domain

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Brown, Sharron A N ^a   Cheng, Emily ^a   Williams, Mark S ^a   Winkles, Jeffrey A ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; CYSTEINE; DIMER; FIBROBLAST GROWTH FACTOR INDUCIBLE 14; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN HEK293; CELL SURFACE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOLYSIS; CYTOPLASM; DIMERIZATION; DISULFIDE BOND; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN BINDING; PROTEIN DOMAIN; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; CELL LINE; CYTOPLASM; DISULFIDES; HUMANS; MOLECULAR SEQUENCE DATA; NF-KAPPA B; PROTEIN ISOFORMS; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, QUATERNARY; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, TUMOR NECROSIS FACTOR; RNA, MESSENGER; SEQUENCE DELETION; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTORS;

EID: 84878668685     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065248     Document Type: Article

References (54)

1. Meighan-Mantha RL, Hsu DKW, Guo Y, Brown SAN, Feng SY, et al. (1999) The mitogen-inducible Fn14 gene encodes a type I transmembrane protein that modulates fibroblast adhesion and migration. J Biol Chem 274: 33166-33176.
2. Feng SY, Guo Y, Factor VM, Thorgeirsson SS, Bell DW, et al. (2000) The Fn14 immediate-early response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas. Am J Pathol 156: 1253-1261.
3. Wiley SR, Cassiano L, Lofton T, Davis-Smith T, Winkles JA, et al. (2001) A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity 15: 837-846.
4. Winkles JA, (2008) The TWEAK-Fn14 cytokine-receptor axis: Discovery, biology and therapeutic targeting. Nat Rev Drug Discov 7: 411-425.
5. Burkly LC, Michaelson JS, Zheng TS, (2011) TWEAK/Fn14 pathway: An immunological switch for shaping tissue responses. Immunol Rev 244: 99-114.
6. Bossen C, Ingold K, Tardivel A, Bodmer JL, Gaide O, et al. (2006) Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human. J Biol Chem 281: 13964-13971.
7. Varfolomeev E, Goncharov T, Maecker H, Zobel K, Komuves LG, et al. (2012) Cellular inhibitors of apoptosis are global regulators of NF-κB and MAPK activation by members of the TNF family of receptors. Sci Signal 5: ra22.
8. Donohue PJ, Richards CM, Brown SA, Hanscom HN, Buschman J, et al. (2003) TWEAK is an endothelial cell growth and chemotactic factor that also potentiates FGF-2 and VEGF-A mitogenic activity. Arterioscler Thromb Vasc Biol 23: 594-600.
9. Li H, Mittal A, Paul PK, Kumar M, Srivastava DS, et al. (2009) Tumor necrosis factor-related weak inducer of apoptosis augments matrix metalloproteinase 9 (MMP-9) production in skeletal muscle through the activation of nuclear factor-κB-inducing kinase and p38 mitogen-activated protein kinase: A potential role of MMP-9 in myopathy. J Biol Chem 284: 4439-4450.
10. Kumar M, Makonchuk DY, Li H, Mittal A, Kumar A, (2009) TNF-like weak inducer of apoptosis (TWEAK) activates proinflammatory signaling pathways and gene expression through the activation of TGF-β-activated kinase 1. J Immunol 182: 2439-2448.
11. Fortin SP, Ennis MJ, Savitch BA, Carpentieri D, McDonough WS, et al. (2009) Tumor necrosis factor-like weak inducer of apoptosis stimulation of glioma cell survival is dependent on Akt2 function. Mol Cancer Res 7: 1871-1881.
12. Tran NL, McDonough WS, Savitch BA, Fortin SP, Winkles JA, et al. (2006) Increased fibroblast growth factor-inducible 14 expression levels promote glioma cell invasion via Rac1 and nuclear factor-κB and correlate with poor patient outcome. Cancer Res 66: 9535-9542.
13. Saitoh T, Nakayama M, Nakano H, Yagita H, Yamamoto N, et al. (2003) TWEAK induces NF-κB2 p100 processing and long lasting NF-κB activation. J Biol Chem 278: 36005-36012.
14. Vince JE, Chau D, Callus B, Wong WW, Hawkins CJ, et al. (2008) TWEAK-Fn14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNF-α. J Cell Biol 182: 171-184.
15. Sanz AB, Sanchez-Nino MD, Izquierdo MC, Jakubowski A, Justo P, et al. (2010) TWEAK activates the non-canonical NF-κB pathway in murine renal tubular cells: Modulation of CCL21. PLoS One 5: e8955.
16. Brown SA, Ghosh A, Winkles JA, (2010) Full-length, membrane-anchored TWEAK can function as a juxtacrine signaling molecule and activate the NF-κB pathway. J Biol Chem 285: 17432-17441.
17. Maecker H, Varfolomeev E, Kischkel F, Lawrence D, LeBlanc H, et al. (2005) TWEAK attenuates the transition from innate to adaptive immunity. Cell 123: 931-944.
18. Jakubowski A, Ambrose C, Parr M, Lincecum JM, Wang MZ, et al. (2005) TWEAK induces liver progenitor cell proliferation. J Clin Invest 115: 2330-2340.
19. Dohi T, Borodovsky A, Wu P, Shearstone JR, Kawashima R, et al. (2009) TWEAK/Fn14 pathway: A nonredundant role in intestinal damage in mice through a TWEAK/intestinal epithelial cell axis. Gastroenterology 136: 912-923.
20. Winkles JA, Tran NL, Brown SA, Stains N, Cunliffe HE, et al. (2007) Role of TWEAK and Fn14 in tumor biology. Front Biosci 12: 2761-2771.
21. Winkles JA, Tran NL, Berens ME, (2005) TWEAK and Fn14: New molecular targets for cancer therapy? Cancer Lett 235: 11-17.
22. Burkly LC, Michaelson JS, Hahm K, Jakubowski A, Zheng TS, (2007) TWEAKing tissue remodeling by a multifunctional cytokine: Role of TWEAK/Fn14 pathway in health and disease. Cytokine 40: 1-16.
23. Culp PA, Choi D, Zhang Y, Yin J, Seto P, et al. (2010) Antibodies to TWEAK receptor inhibit human tumor growth through dual mechanisms. Clin Cancer Res 16: 497-508.
24. Whitsett TG, Cheng E, Inge L, Asrani K, Jameson NM, et al. (2012) Elevated expression of Fn14 in non-small cell lung cancer correlates with activated EGFR and promotes tumor cell migration and invasion. Am J Pathol 181: 111-120.
25. Zhou H, Ekmekcioglu S, Marks JW, Mohamedali KA, Asrani K, et al. (2013) The TWEAK receptor Fn14 is a therapeutic target in melanoma: Immunotoxins targeting Fn14 receptor for malignant melanoma treatment. J Invest Dermatol 133: 1052-1062.
26. Chao DT, Su M, Tanlimco S, Sho M, Choi D, et al. (2013) Expression of TweakR in breast cancer and preclinical activity of enavatuzumab, a humanized anti-TweakR mAb. J Cancer Res Clin Oncol 139: 315-325.
27. Michaelson JS, Amatucci A, Kelly R, Su L, Garber E, et al. (2011) Development of an Fn14 agonistic antibody as an anti-tumor agent. MAbs 3: 362-375.
28. Michaelson JS, Kelly R, Yang L, Zhang X, Wortham K, et al. (2012) The anti-Fn14 antibody BIIB036 inhibits tumor growth in xenografts and patient derived primary tumor models and enhances efficacy of chemotherapeutic agents in multiple xenograft models. Cancer Biol Ther 13: 812-821.
29. Ho DH, Vu H, Brown SAN, Donohue PJ, Hanscom HN, et al. (2004) Soluble tumor necrosis factor-like weak inducer of apoptosis overexpression in HEK293 cells promotes tumor growth and angiogenesis in athymic nude mice. Cancer Res 64: 8968-8972.
30. Zhou H, Marks JW, Hittelman WN, Yagita H, Cheung LH, et al. (2011) Development and characterization of a potent immunoconjugate targeting the Fn14 receptor on solid tumor cells. Mol Cancer Ther 10: 1276-1288.
31. Tran NL, McDonough WS, Donohue PJ, Winkles JA, Berens TJ, et al. (2003) The human Fn14 receptor gene is up-regulated in migrating glioma cells in vitro and overexpressed in advanced glial tumors. Am J Pathol 162: 1313-1321.
32. Willis AL, Tran NL, Chatigny JM, Charlton N, Vu H, et al. (2008) The fibroblast growth factor-inducible 14 receptor is highly expressed in HER2-positive breast tumors and regulates breast cancer cell invasive capacity. Mol Cancer Res 6: 725-734.
33. Tran NL, McDonough WS, Savitch BA, Sawyer TF, Winkles JA, et al. (2005) The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling system regulates glioma cell survival via NF-κB pathway activation and BCL-XL/BCL-W expression. J Biol Chem 280: 3483-3492.
34. Watts GS, Tran NL, Berens ME, Bhattacharyya AK, Nelson MA, et al. (2007) Identification of Fn14/TWEAK receptor as a potential therapeutic target in esophageal adenocarcinoma. Int J Cancer 121: 2132-2139.
35. Huang M, Narita S, Tsuchiya N, Ma Z, Numakura K, et al. (2011) Overexpression of Fn14 promotes androgen-independent prostate cancer progression through MMP-9 and correlates with poor treatment outcome. Carcinogenesis 32: 1589-1596.
36. Fortin SP, Ennis MJ, Schumacher CA, Zylstra-Diegel CR, Williams BO, et al. (2012) Cdc42 and the guanine nucleotide exchange factors Ect2 and Trio mediate Fn14-induced migration and invasion of glioblastoma cells. Mol Cancer Res 10: 958-968.
37. Blanco-Colio LM, Martin-Ventura JL, Munoz-Garcia B, Orbe J, Paramo JA, et al. (2007) Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis. Arterioscler Thromb Vasc Biol 27: 916-922.
38. Jain M, Jakubowski A, Cui L, Shi J, Su L, et al. (2009) A novel role for tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in the development of cardiac dysfunction and failure. Circulation 119: 2058-2068.
39. Rubin JB, Kung AL, Klein RS, Chan JA, Sun Y, et al. (2003) A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Nat Acad Sci USA 100: 13513-13518.
40. Keren H, Lev-Maor G, Ast G, (2010) Alternative splicing and evolution: Diversification, exon definition and function. Nat Rev Genet 11: 345-355.
41. Brown SAN, Hanscom HN, Vu H, Brew SA, Winkles JA, (2006) TWEAK binding to the Fn14 cysteine-rich domain depends on charged residues located in both the A1 and D2 modules. Biochem J 397: 297-304.
42. Foley SF, Sun Y, Zheng TS, Wen D, (2008) Picomole-level mapping of protein disulfides by mass spectrometry following partial reduction and alkylation. Anal Biochem 377: 95-104.
43. He F, Dang W, Saito K, Watanabe S, Kobayashi N, et al. (2009) Solution structure of the cysteine-rich domain in Fn14, a member of the tumor necrosis factor receptor superfamily. Protein Sci 18: 650-656.
44. Brown SAN, Richards CM, Hanscom HN, Feng SL, Winkles JA, (2003) The Fn14 cytoplasmic tail binds tumour necrosis factor receptor associated factors 1, 2, 3 and 5 and mediates nuclear factor-κB activation. Biochem J 371: 395-403.
45. Han S, Yoon K, Lee K, Kim K, Jang H, et al. (2003) TNF-related weak inducer of apoptosis receptor, a TNF receptor superfamily member, activates NF-κB through TNF receptor-associated factors. Biochem Biophys Res Commun 305: 789-796.
46. Locksley RM, Killeen N, Lenardo MJ, (2001) The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell 104: 487-501.
47. Valley CC, Lewis AK, Mudaliar DJ, Perlmutter JD, Braun AR, et al. (2012) Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces death receptor 5 networks that are highly organized. J Biol Chem 287: 21265-21278.
48. Chan FK, Chun HJ, Zheng L, Siegel RM, Bui KL, et al. (2000) A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 288: 2351-2354.
49. Yousaf N, Gould DJ, Aganna E, Hammond L, Mirakian RM, et al. (2005) Tumor necrosis factor receptor I from patients with tumor necrosis factor receptor-associated periodic syndrome interacts with wild-type tumor necrosis factor receptor I and induces ligand-independent NF-κB activation. Arthritis Rheum 52: 2906-2916.
50. Chan FK, (2007) Three is better than one: Pre-ligand receptor assembly in the regulation of TNF receptor signaling. Cytokine 37: 101-107.
51. Naismith JH, Devine TQ, Brandhuber BJ, Sprang SR, (1995) Crystallographic evidence for dimerization of unliganded tumor necrosis factor receptor. J Biol Chem 270: 13303-13307.
52. Horie R, Watanabe T, Morishita Y, Ito K, Ishida T, et al. (2002) Ligand-independent signaling by overexpressed CD30 drives NF-κB activation in Hodgkin-Reed-Sternberg cells. Oncogene 21: 2493-2503.
53. Kanazawa K, Kudo A, (2005) Self-assembled RANK induces osteoclastogenesis ligand-independently. J Bone Miner Res 20: 2053-2060.
54. Mehl AM, Jones M, Rowe M, Brennan P, (2001) Characterization of a CD40-dominant inhibitory receptor mutant. J Immunol 167: 6388-6393.